Common use of THE PROGRAMME Clause in Contracts

THE PROGRAMME. 2.1 As soon as reasonably practicable following signing this Agreement, Lilly shall provide Peptide with sufficient quantity of each of the Target Proteases required for the Programme and any information necessary or useful for the assay of each of the Target Proteases. 2.2 Peptide agrees to use reasonable endeavours to carry out the Programme and to deliver to Lilly the Report and the Data for each of the Target Proteases by December 31, 1998 or as soon as is reasonably practicable. In addition, if Peptide has identified a FRET Substrate for any of the Target Proteases, Peptide will supply Lilly with approximately 10 mg of such Substrate for evaluation by Lilly. If the generic library does not give a hit for a Target Protease, then Peptide shall still supply any Data to Lilly for evaluation. 2.3 Lilly, at its sole option, may enter into a Technology Transfer Agreement with Peptide by providing Peptide with notice of the same at any time during the Option Period pursuant to terms negotiated by the parties in good faith that are consistent with the terms described in Addendum I and other terms that are customary under similar circumstances. For purposes of this Agreement the term "Option Period" shall mean the period commencing on the effective date of this Agreement and ending on the later of either: (i) December 31, 1999 or (ii) four months after Lilly has received all Data, Substrates and Report as contemplated under this Agreement.

THE PROGRAMME. 2.1 As soon as reasonably practicable following signing this Agreement, Lilly shall provide Peptide with sufficient quantity of each of the Target Proteases required for the Programme and any information necessary or useful for the assay of each of the Target Proteases. 2.2 Peptide agrees to use reasonable endeavours to carry out the Programme and to deliver to Lilly the Report and the Data for each of the Target Proteases by December 31, 1998 []* or as soon as is reasonably practicable. In addition, if Peptide has identified a FRET Substrate for any of the Target Proteases, Peptide will supply Lilly with approximately 10 mg of such Substrate for evaluation by Lilly. If the generic library does not give a hit for a Target Protease, then Peptide shall still supply any Data to Lilly for evaluation. 2.3 Lilly, at its sole option, may enter into a Technology Transfer Agreement with Peptide by providing Peptide with notice of the same at any time during the Option Period pursuant to terms negotiated by the parties in good faith that are consistent with the terms described in Addendum I and other terms that are customary under similar circumstances. For purposes of this Agreement the term "Option Period" shall mean the period commencing on the effective date of this ---------- * This portion of the Exhibit has been omitted pursuant to a request for Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended. The Complete Exhibit, including the portions for which confidential treatment has been requested, has been filed separately with the Securities and Exchange Commission. Agreement and ending on the later of either: (i) December 31, 1999 or (ii) four months after Lilly has received all Data, Substrates and Report as contemplated under this Agreement.[]*

THE PROGRAMME. 2.1 As soon as reasonably practicable following signing this Agreement, Lilly shall provide Peptide with sufficient quantity of each of the Target Proteases required for the Programme and any information necessary or useful for the assay of each of the Target Proteases. 2.2 Peptide agrees to use reasonable endeavours to carry out the Programme and to deliver to Lilly the Report and the Data for each of the Target Proteases by December 31, 1998 or as soon as is reasonably practicable. In addition, if Peptide has identified a FRET Substrate for any of the Target Proteases, Peptide will supply Lilly with approximately 10 mg of such Substrate for evaluation by Lilly. If the generic library does not give a hit for a Target Protease, then Peptide shall still supply any Data to Lilly for evaluation. 2.3 Lilly, at its sole option, may enter into a Technology Transfer Agreement with Peptide by providing Peptide with notice of the same at any time during the Option Period pursuant to terms negotiated by the parties in good faith that are consistent with the terms described in Addendum I and other terms that are customary under similar circumstances. For purposes of this Agreement the term "Option Period" shall mean the period commencing on the effective date of this Agreement and ending on the later of either: (i) December 31, 1999 or (ii) four months after Lilly has received all Data, Substrates and Report as contemplated under this Agreement.[]*